Payment overview · 2025
General Payments
$1,406.60
78 reported records · 22 companies
Healthcare provider profile · identity verified
Jonathan Lyle Manzer, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CARTHAGE, MO · NPI 1407848971
Verified facts
What the public records show
CMS Open Payments records show Jonathan Lyle Manzer, M.D. received $1,406.60 in general payments during 2025 across 78 reported records.
AstraZeneca Pharmaceuticals LP accounted for 15.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Nurtec Odt, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $211.87 | 15.1% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $148.03 | 10.5% | 13 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $134.72 | 9.6% | 8 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $127.76 | 9.1% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $98.93 | 7.0% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $81.96 | 5.8% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $61.04 | 4.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $59.62 | 4.2% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $56.82 | 4.0% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $53.57 | 3.8% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $53.24 | 3.8% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $52.10 | 3.7% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.64 | 3.4% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $42.05 | 3.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $35.14 | 2.5% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $31.48 | 2.2% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.10 | 1.8% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $18.74 | 1.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.69 | 1.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.23 | 1.2% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $17.16 | 1.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.71 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,406.60 | 78 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $134.72 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $134.51 | 5 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $127.76 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $111.46 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $111.26 | 11 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $106.49 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $63.69 | 4 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $62.93 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $61.04 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $53.57 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $53.24 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $42.05 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $40.77 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $40.77 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $36.77 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $36.77 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $36.00 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $35.14 | 2 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $34.58 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $31.48 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.90 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $29.72 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $28.52 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $27.57 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $27.57 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $25.10 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.69 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 85 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 25 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 47 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 102 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 51 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 31 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | 12 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
85 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
31 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
102 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
85 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 427 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 326 | 118 |
| Gabapentin | Gabapentin | 255 | 97 |
| Atorvastatin Calcium | Atorvastatin Calcium | 244 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 174 | 79 |
| Omeprazole | Omeprazole | 174 | 64 |
| Methylprednisolone | Methylprednisolone | 172 | 134 |
| Metformin Hcl | Metformin Hcl | 166 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 165 | 69 |
| Lisinopril | Lisinopril | 163 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 160 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 139 | 65 |
| Meloxicam | Meloxicam | 135 | 62 |
| Trazodone Hcl | Trazodone Hcl | 128 | 50 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 121 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 116 | 45 |
| Losartan Potassium | Losartan Potassium | 116 | 55 |
| Montelukast Sodium | Montelukast Sodium | 113 | 49 |
| Azithromycin | Azithromycin | 112 | 87 |
| Tizanidine Hcl | Tizanidine Hcl | 110 | 36 |
| Alprazolam | Alprazolam | 105 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 103 | 46 |
| Mounjaro | Tirzepatide | 102 | 21 |
| Sertraline Hcl | Sertraline Hcl | 98 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 32 |
| Topiramate | Topiramate | 94 | 32 |
| Benztropine Mesylate | Benztropine Mesylate | 91 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 90 | 31 |
| Furosemide | Furosemide | 90 | 45 |
| Prednisone | Prednisone | 90 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 90 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 29 |
| Levofloxacin | Levofloxacin | 88 | 61 |
| Eliquis | Apixaban | 85 | 23 |
| Carvedilol | Carvedilol | 80 | 37 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 80 | 33 |
| Famotidine | Famotidine | 76 | 28 |
| Potassium Chloride | Potassium Chloride | 73 | 34 |
| Aripiprazole | Aripiprazole | 70 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 66 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 65 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 29 |
| Glimepiride | Glimepiride | 64 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 64 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 63 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 37 |
| Buspirone Hcl | Buspirone Hcl | 59 | 24 |
| Pregabalin | Pregabalin | 57 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 55 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 24 |
| Ozempic | Semaglutide | 51 | 15 |
| Sucralfate | Sucralfate | 50 | 22 |
| Jardiance | Empagliflozin | 47 | 12 |
| Fluconazole | Fluconazole | 46 | 31 |
| Prazosin Hcl | Prazosin Hcl | 45 | 15 |
| Alendronate Sodium | Alendronate Sodium | 44 | suppressed |
| Amoxicillin | Amoxicillin | 44 | 25 |
| Clozapine | Clozapine | 44 | suppressed |
| Levetiracetam | Levetiracetam | 44 | 12 |
| Divalproex Sodium | Divalproex Sodium | 43 | 17 |
| Allopurinol | Allopurinol | 42 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 40 |
| Olanzapine | Olanzapine | 42 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | 15 |
| Lorazepam | Lorazepam | 40 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 40 | 11 |
| Spironolactone | Spironolactone | 40 | 15 |
| Ondansetron Odt | Ondansetron | 39 | 32 |
| Celecoxib | Celecoxib | 38 | 17 |
| Nortriptyline Hcl | Nortriptyline Hcl | 38 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 38 | 14 |
| Simvastatin | Simvastatin | 37 | 16 |
| Tramadol Hcl | Tramadol Hcl | 37 | 12 |
| Cephalexin | Cephalexin | 36 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | 15 |
| Baclofen | Baclofen | 35 | 12 |
| Donepezil Hcl | Donepezil Hcl | 35 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 33 |
| Bupropion Xl | Bupropion Hcl | 34 | 15 |
| Ibuprofen | Ibuprofen | 34 | 13 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 33 | 12 |
| Mirtazapine | Mirtazapine | 33 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 19 |
| Tresiba Flextouch U-200 | Insulin Degludec | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | 14 |
| Lactulose | Lactulose | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 18 |
| Risperidone | Risperidone | 32 | 13 |
| Trulicity | Dulaglutide | 32 | 12 |
| Cefdinir | Cefdinir | 31 | 17 |
| Clonidine Hcl | Clonidine Hcl | 31 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | 14 |
| Lithium Carbonate | Lithium Carbonate | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | 12 |
| Metformin Hcl Er | Metformin Hcl | 29 | 14 |
| Diazepam | Diazepam | 28 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | 14 |
| Atenolol | Atenolol | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | 12 |
| Finasteride | Finasteride | 25 | suppressed |
| Nystatin | Nystatin | 25 | 14 |
| Glipizide | Glipizide | 24 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 24 | suppressed |
| Fetzima | Levomilnacipran Hcl | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 21 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | 12 |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Insulin Lispro | Insulin Lispro | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | 12 |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 11 | suppressed |
| Humira(Cf) Pen | Adalimumab | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,406.60 · 78 records | AstraZeneca Pharmaceuticals LP | ABILIFY ASIMTUFII, ABILIFY MAINTENA, AIRSUPRA, AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, COBENFY, Dexcom G6 Transmitter, ELIQUIS, FANAPT, FARXIGA, HETLIOZ, JARDIANCE, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, REXULTI, REZDIFFRA, Rybelsus, Senza, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, UZEDY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, XYOSTED, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error